( in all treatment groups. No cli...)Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy,Health

in all treatment groups. No clinically significant changes in glucose or lipids were seen with nebivolol monotherapy during the study. -- "Addition of the Beta-Blocker Nebivolol to Ongoing Therapy in the Management of Mild-to-Moderate Hypertension" by Alan H. Gradman, MD, Chief, Division of Cardiovascular Diseases, The Western Pennsylvania Hospital. [Poster Presentation, P-383: Monday, May 21 from 12 pm to 1 pm (Riverside Hall)] The blood pressure lowering effects and tolerability of nebivolol added to ongoing antihypertensive therapy in patients was evaluated in this 12-week, randomized, double-blind, placebo-controlled study (n=669). Results indicate that, by comparison to placebo, nebivolol incrementally lowers blood pressure in mild to moderate hypertensive patients when added to ongoing antihypertensive therapy consisting of one or two medications from the following classes: ACE inhibitors, ARBs, or diuretics, with an incidence of reported adverse events similar to placebo. -- "Efficacy of the Novel Beta-blocker Nebivolol in Obese and Non-Obese Hypertensive Patients" by James R. Sowers, MD, Professor of Medicine and Physiology, Director Diabetes and Cardiovascular Center, University of Missouri. [Poster Presentation, P-442: Monday, May 21 from 12 pm to 1 pm (Riverside Hall)] The blood pressure lowering effects of nebivolol was compared in non- obese and obese hypertensive patients, a population that typically has a poorer response to treatment and an increased need for multiple medications. The pooled analysis of three randomized, double-blind, placebo-controlled trials of similar design was stratified by patient obesity status (BMI greater than or equal to 30 kg/m2) at baseline (obese, n=878; non-obese, n=1136). Results suggest that once-
'"/>




Page: 1 2 3 4
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes